- Home
- IQV vs LVS Comparison
IQV vs LVS Comparison
Compare IQV & LVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQV
- LVS
- Stock Information
- Founded
- IQV 1982
- LVS 1988
- Country
- IQV United States
- LVS United States
- Employees
- IQV N/A
- LVS N/A
- Industry
- IQV Biotechnology: Commercial Physical & Biological Resarch
- LVS Hotels/Resorts
- Sector
- IQV Health Care
- LVS Consumer Discretionary
- Exchange
- IQV Nasdaq
- LVS Nasdaq
- Market Cap
- IQV 31.6B
- LVS 32.4B
- IPO Year
- IQV 2013
- LVS 2004
- Fundamental
- Price
- IQV $174.35
- LVS $39.04
- Analyst Decision
- IQV Strong Buy
- LVS Buy
- Analyst Count
- IQV 18
- LVS 14
- Target Price
- IQV $248.72
- LVS $59.38
- AVG Volume (30 Days)
- IQV 1.5M
- LVS 5.1M
- Earning Date
- IQV 05-01-2025
- LVS 04-16-2025
- Dividend Yield
- IQV N/A
- LVS 2.56%
- EPS Growth
- IQV 2.74
- LVS 22.50
- EPS
- IQV 7.49
- LVS 1.96
- Revenue
- IQV $15,405,000,000.00
- LVS $11,298,000,000.00
- Revenue This Year
- IQV $4.25
- LVS $9.44
- Revenue Next Year
- IQV $6.17
- LVS $5.62
- P/E Ratio
- IQV $23.21
- LVS $19.89
- Revenue Growth
- IQV 2.81
- LVS 8.93
- 52 Week Low
- IQV $169.11
- LVS $36.62
- 52 Week High
- IQV $252.88
- LVS $56.61
- Technical
- Relative Strength Index (RSI)
- IQV 35.36
- LVS 32.71
- Support Level
- IQV $169.37
- LVS $37.38
- Resistance Level
- IQV $188.39
- LVS $39.29
- Average True Range (ATR)
- IQV 4.83
- LVS 1.12
- MACD
- IQV -0.79
- LVS -0.37
- Stochastic Oscillator
- IQV 25.16
- LVS 23.88
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore toward the end of 2028. Its Venetian and Palazzo Las Vegas assets in the U.S. were sold to Apollo and VICI in 2022. With the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.